Cornerstone Capital, Inc. Viking Therapeutics, Inc. Transaction History
Cornerstone Capital, Inc.
- $920 Million
- Q1 2025
A detailed history of Cornerstone Capital, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cornerstone Capital, Inc. holds 24,280 shares of VKTX stock, worth $682,268. This represents 0.06% of its overall portfolio holdings.
Number of Shares
24,280
Previous 24,800
2.1%
Holding current value
$682,268
Previous $997,000
41.22%
% of portfolio
0.06%
Previous 0.11%
Shares
26 transactions
Others Institutions Holding VKTX
# of Institutions
431Shares Held
65.2MCall Options Held
8.28MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$286 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$169 Million0.01% of portfolio
-
State Street Corp Boston, MA4.06MShares$114 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$87.9 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.12MShares$87.7 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.15B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...